MedTrace Logo

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

NCT06951503 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 560

Last updated 2026-03-04

No results posted yet for this study

Summary

This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.

Conditions

  • Colorectal Adenocarcinoma

Interventions

DRUG

AK112

iv, q2w

DRUG

Oxaliplatin

iv, q2w

DRUG

Irinotecan

iv, q2w

DRUG

Leucovorin and 5-FU

iv, q2w

DRUG

Bevacizumab

iv, q2w

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2027-01-13
Completion
2029-01-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06951503 on ClinicalTrials.gov